We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Prognostic Panel Helps Identify Lupus Patients at Risk for Kidney, Brain, or Cardiovascular Involvement

By LabMedica International staff writers
Posted on 24 Jun 2014
In response to physician requests to help fulfill an unmet need, the new prognostic test helps assess potential risk of various Lupus related complications.

Lupus patients can suffer from disease flares that can become destructive to any organ or tissue in the body. More...
Exagen Diagnostics, Inc. (Albuquerque, NM, USA), a leading diagnostics development company focused in rheumatology, has launched the addition of "Avise SLE Prognostic" to its testing services. Designed to supplement the "Avise SLE+ Connective Tissue" diagnostic, the Avise SLE Prognostic panel helps physicians assess potential risk for lupus nephritis, neuropsychiatric SLE (Systemic lupus erythematosus), thrombosis, and cardiovascular events.

The prognostic panel was developed in response to physician requests to help fulfill an unmet need in the rheumatology space. The panel includes the following markers: anti-C1q – prognostic factor for lupus nephritis; anti-Ribosomal P – prognostic factor for neuropsychiatric SLE; and anti-phosphatidylserine/prothrombin (PS/PT) (IgM, IgG) – prognostic factor for thrombosis in SLE. Also, prognostic factors for thrombosis and cardiovascular events – anti-cardiolipin (IgM, IgG, IgA) and anti-β2-Glycoprotein 1 (IgM, IgG, IgA) – are indirectly included in the Avise SLE+ Connective Tissue 2.0 diagnostic or as an add-on to Avise SLE 2.0.

Complimenting Avise SLE 2.0 or Avise SLE+ Connective Tissue 2.0, Avise SLE Prognostic uses the same blood draw specimen as for the diagnostic and offers pre-provided kits, pre-paid Fedex, limited patient out-of-pocket cost, and high quality data based results within 7 days.

"We are pleased to provide an additional tool to help support physicians with their clinical assessment and treatment of patients. This launch furthers our commitment to providing access to quality serologic testing to all patients," said Ron Rocca, Exagen President and CEO.

Related Links:
Exagen Diagnostics
Avise Tests



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.